Défaut d’observance aux médicaments antiostéoporotiques : croisement de deux techniques, la clef pour l’évaluation de l’observance ?

Saliba, Layla; Boisson, Laura; Sallerin, Brigitte; Laroche, Michel; Despas, Fabien

doi:10.2515/therapie/2014028

Cited by 1 publication

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because most OA patients are elderly and suffering from comorbidities, contraindicating the use of NSAIDs, 13 it is logical to prescribe CS or GS as first-line therapies, giventheir excellent tolerance profile, in OA patients whose pain is not sufficiently relieved by nonpharmacological modalities and analgesics 29. However, as in many other chronic conditions, the main concern with OA therapy is obtaining good medication compliance over a long period 30–32…”

Section: Introductionmentioning

confidence: 99%

<p>Predictive factors of adherence to an association of glucosamine sulfate, copper, and ginger extracts in patients with symptomatic osteoarthritis: a prospective open-label French noninterventional study (the PREDOA study)</p>

Conrozier¹,

Renevier²,

Parisaux³

et al. 2019

PPA

View full text Add to dashboard Cite

Background: Osteoarthritis (OA) management needs a combination of nonpharmacological and pharmacological modalities. However, as in many chronic conditions, the main concern with OA therapy is the difficulty in obtaining good medication compliance over a long period. The PREDOA study aimed to investigate the predictive factors of adherence to treatment in patients with OA treated with glucosamine sulfate (GS)–copper sulfate–ginger root (GCu), a symptomatic slow-acting drug for OA. Methods: Ambulatory patients with a clinical diagnosis of OA were included in a prospective (6 months) multicenter open-label observational study. All patients received two capsules of GS-GCu once daily for 6 months. Demographics, disease features (OA location, symptom duration, concomitant therapies, comorbidities), and patient self-assessment of pain (0–10) were obtained at baseline. At month 6, the investigator collected patient self-assessments of treatment observance, reasons for nonadherence, pain scores, patient perceptions of treatment efficacy, changes in analgesic intake, and occurrence of adverse events. Predictors of observance were studied in univariate and multivariate analyses. Results: A total of 2,030 patients were included in the study. At baseline, the average pain score was 6.4±1.7. Observance was good in 80% of patients. It was weaker in active than retired patients ( P =0.005) in patients not taking concomitant treatment ( P =0.008) or who had never been treated for OA ( P =0.001). Observance was correlated with pain decrease ( P <0.0001) and with lack of adverse effects ( P <0.001). Age, sex, pain level at baseline, OA location, and number of painful joints were not related to treatment compliance. Conclusion: Medication compliance with GS-GCu depends both on the safety–efficacy balance and several patient related-factors. To improve adherence, detailed information about therapeutic objectives is necessary in active patients who do not get any other medications and for whom it is their first treatment for OA. Clinical trial identifier: CCTIRS 14-371 B.

show abstract

Section: Introductionmentioning

confidence: 99%